Medical device manufacturer Prollenium has acquired topical hyaluronidase Topilase.
The company explains that Topilase enables treatment adjustment without injecting product or introducing excessive product, as well as minimising over-correction and natural hyaluronic acid degradation. The product is made of a combination of enzymes concentrated within a dispersing agent, helping it to permeate the skin successfully, with the benefit of five additional natural ingredients: cistus, myrrh, lavender, aloe vera and helichrysum essential oils to restore, soothe, purify, revitalise and regenerate, explains Prollenium.
The enzyme complex within Topilase contains protease, lipase and hyaluronidase which helps to break down HA chains. According to the company, on average, patients require three treatments one week apart. The product is applied to the treated area and should be spread using a brush or gloved hands. The area should be massaged well for one to two minutes, explains the company.
Ario Khoshbin, founder and CEO of Prollenium, said, “Today we further demonstrate our commitment to providing best-in-class products to support safety, efficacy and expertise in the cosmetic aesthetics global market. We have made yet another exciting acquisition and it is no exaggeration to say that Topilase will likely revolutionise the practice of injectable enhancement ensuring both patient safety and treatment outcome.”
